There are 26 records that matched your search criteria

Date Title Category
22-Jul-2010 The statement warned: "Contraindicated In Children Under 2 Years of Age" that must be filled in the package insert of all products carbocysteine, acetylcarbocysteine and methylcarbocysteine (Mecysteine)
Bil (54) dlm. BPFK/PPP/01/03 dated 22nd Jul 2010
DCA letters
25-May-2010 The Full evaluation launch module of QUEST3
Bil (45) dlm. BPFK/PPO/03/02 Bhg 3 dated 25th May 2010
DCA letters
14-Apr-2010 Rules and regulation drug control regulations and cosmetics 1984 (Amendment 2006). Instruction numbers for two years in 2010. NPCB Circular on
Bil (49) dlm. BPFK/PPP/01/03 dated 14th April 2010
DCA letters
14-Sep-2010 Products use on the male/female genitals for sexual purposes which is not categories as cosmetic classification
Bil (41) dlm. BPFK/17/K/2.2 dated 14th Sept 2009
DCA letters
23-Feb-2011 PhAMA: NKEA - Pemandu Steering committee mtg - 22nd Feb 2011 @ 10 a.m
General News
14-Feb-2012 PhAMA Press Release on the 'Launching of the PhAMA Industry Fact Book, officiated by the Minister of Health, Y.B. Dato' Sri Liow Tiong Lai
Hilton KL
General News
12-May-2010 PhAMA participated in the NKEA Workshop organized by PEMANDU.
On 12 May 2010 at the Malaysia Airlines Academy, PhAMA participated in the National Key Economic Areas (NKEA)...
General News
23-Feb-2011 PhAMA Annual Games 2011
General News
23-Feb-2011 PhAMA 39th AGM Notice - 31 March 2011
General News
25-May-2010 NPCB Circular on Quest 3 launch
Bil (49) dlm. BPFK/PPO/03/02 dated 25th May 2010
NPCB
04-Mar-2015 News Coverage on GST Media Roundtable
General News
14-Jun-2011 MyIPO-PhAMA IP Seminar on Intellectual Property: 'The Way Forward' - Post event Videos and Photos
The MyIPO-PhAMA IP Seminar on Intellectual Property: "The Way Forward", was held on Tuesday 14 June 2011 at the...
14-Jun-2011 Joint MyIPO-PhAMA Seminar on '1 Malaysia Medicines: The Way Forward in Intellectual Property'
MyIPO Office, Level 12A, Menara UOA, Jalan Bangsar Utama 1, Bangsar, Kuala Lumpur
15-Mar-2016 Introduction and List of PhAMA Training Premises for Provisionally Registered Pharmacist (PRP)
General News
16-Aug-2010 Cosmetic products that are use around the eye and packaging that are not permitted for the product.
Bil (40) dlm. BPFK/17/K/2.2 dated 16th Aug 2010
DCA letters
13-Oct-2009 Caution Statement on “Severe Drug Interaction Between Colchicine and P-Glycoprotein or Strong CYP3A4 Inhibitors” required to be included in the product package insert for Colchicine
Bil (44) dlm. BPFK/PPP/01/03 dated 13th October 2009
DCA letters
14-Sep-2009 Caution Statement on “Potential for an Increase in Risk of Suicidal Thoughts or Behaviours” required to be included in the product package insert for Antiepileptik.
Bil (43) dlm. BPFK/PPP/01/03 dated 14th Sept 2009
DCA letters
14-Sep-2009 Caution Statement on “Potential For an increase in risk of Hepatotoxicity” required to be included in the product package insert for Propylthiouracil
Bil (41) dlm. BPFK/PPP/01/03 dated 14th Sept 2009
DCA letters
14-Sep-2009 Caution Statement on “Potential For an increase in risk of Hepatotoxicity” required to be included in the product package insert for Propylthiouracil
Bil (41) dlm. BPFK/PPP/01/03 dated 14th Sept 2009
DCA letters
14-Sep-2009 Caution Statement on “Possible Interaction between Clopidogrel and Proton Pump Inhibitors” required to be included in the product package insert for Clopidogrel
Bil (42) dlm. BPFK/PPP/01/03 dated 14th Sept 2009
DCA letters